

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/776,781	09/776,781 02/06/2001		Jacques Theze	202930US0CIP	3255
22850	7590	02/19/2004		EXAM	INER
•		MCCLELLAND, 1	MERTZ, PREMA MARIA		
1940 DUKE STREET ALEXANDRIA, VA 22314				ART UNIT	PAPER NUMBER

DATE MAILED: 02/19/2004



Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Advisory Action	09/776,781	THEZE ET AL.					
Advisory Action	Examiner	Art Unit					
	Prema M Mertz	1646					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may <u>only</u> be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.							
PERIOD FOR REPLY [check either a) or b)]							
a) The period for reply expires <u>4</u> months from the mailing date of the final rejection.							
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.							
2. The proposed amendment(s) will not be entered because:							
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);							
(b) they raise the issue of new matter (see Note below);							
(c) ☑ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal, and/or							
(d) They present additional claims without canceling a corresponding number of finally rejected claims.							
NOTE:							
3. Applicant's reply has overcome the following reject							
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).							
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.							
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were newly					
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we							
The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed:							
Claim(s) objected to: 18 and 27.							
Claim(s) rejected: <u>16, 19-26, 28-32, 38-41</u> .							
Claim(s) withdrawn from consideration:							
B.☐ The drawing correction filed on is a)☐ approved or b)☐ disapproved by the Examiner.							
9. Note the attached Information Disclosure Statemer	nt(s)( PTO-1449) Paper No(s)						
10.  Other:							
		Prema Mul- Prema M Mertz Primary Examiner Art Unit: 1646					

Continuation of 5. does NOT place the application in condition for allowance because: Applicants have amended the claims but failed to obviate the 35 USC 112, second para rejection. Applicants argue that the Moreau et al (1995) reference clearly shows specific binding to the IL-2R beta chain. However, contrary to applicants arguments, the monoclonal antibody of the reference selectively blocks the IL-2 binding to its receptor on TS1 alpha cells (see abstract of reference and Figures 1-3 on page 1050). This is in contrast to the recitiation in claim 16 which recites "...exhibits IL-2 R beta-chain binding activity". Furthermore, it is suggested that claim 16, line 2, be amended to recite "...or an amino acid sequence that is at least 75% identical thereto....".